Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
150.1 USD | +1.54% | +0.29% | -21.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.60% | 18.98B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.63% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B | |
-9.26% | 11.05B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023